Janssen Research & Development has begun its Phase IIb study of combination of simeprevir, odalasvir and AL-335 to treat chronic hepatitis C virus infection without cirrhosis.
Simeprevir (Olysio) is a macrocyclic compound that non-covalently fuses with and inhibits a NS3/4A hepatitis C virus (HCV) protease, which is considered responsible for cleaving and processing the HCV-encoded polyprotein.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Developed by Achillion Pharmaceuticals, odalasvir (ACH 3102) is an orally administered, pan-genotypic, second-generation hepatitis C virus (HCV) NS5A inhibitor.
AL-335, also known as JNJ-4178, is a novel uridine nucleotide analog.
The Phase IIb study is being undertaken as a global, multi-centre study across sites in North America, Europe and Asia, and is a part of Janssen’s global development programme for JNJ-4178.
The study is intended to evaluate the efficacy and safety, as well as determine the pharmacokinetics profile of the JNJ-4178 / AL-335, odalasvir and simeprevir while examining treatment-naive and treatment-experienced non-cirrhotic patients with chronic hepatitis C virus genotype 1, 2, 4, 5, and 6 infection.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt is primarily focused on achieving the percentage of patients with a sustained virological response induced by the drug combination post-treatment.
During the study, the patients will be administered with the triple combination for either six or eight weeks.
